 
 
 
 
Protocol : J2N-MC-JZNW  (a) 
 
A Phase 1, Open -Label, Drug Interaction Study to Investigate the Effect of Single 
and Multiple Doses of Pirtobrutinib on the Pharmacokinetics of Rosuvastatin in 
Healthy Participants  
 
[STUDY_ID_REMOVED]  
 
Approval Date: 22 -Dec-2021  
 
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
1Title Page
Confidential Information
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the p roperty of 
Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical 
investigation of pirtobrutinib (LY3527727 ), unless such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsi diaries. 
Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any pu blic release. 
In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries .
Protocol Title:
APhase 1, Open -Label , Drug Interacti on Study  to Invest igate the Effect of Single and Mult iple 
Doses of Pi rtobruti nib on the Pharmacokinet ics of Rosuvastatin in Healthy Participants
Protocol Number: J2N-MC-JZNW
Amendment Number: (a)
Compound : Pirtobrutinib (LY3527727 )
Brief Title: 
A drug interaction study  invest igating the effect of pirtobrutinib on the pharmacokinet ics of 
rosuvastatin. 
Study Phase: 1 
Sponsor Name: Eli Lilly  and Com pany on behalf of Loxo Onocolgy, Inc., a wholly owned
subsidiary  of Eli Lilly and Co mpany
Legal Registered Address: Indianapo lis, Indiana 46285, USA
Regulatory Agency Identifier Number(s)
IND: 139876
Approval Date: Protocol Amendment (a) Electronically Signed and Approved by Lilly ondate 
provi ded below.
Approval Date: 22-Dec-2021 GMT
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
2Medical Monitor Name and Contact Information will be provided separately .
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
3Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Original Protocol 22-Oct-2021
Amendment (a)
This amendment is considered to be non-substantial.
Overall Rationale for the Amendment:
Section # and Name Description of Change Brief Rationale
1.3. Schedule of 
Activities (SoA)Added footnote ‘g’ describing the 
allowed sampling windows for 
pirtobrutinib and rosuvastatin PK. To provi de clarificat ion to the 
siteand for consistency  with the 
database . 
4.1. Overall Design Removed ‘single -site’ from the 
descript ion of the study .A second site has been added to 
conduct the study  and therefore 
‘single -site’ no l onger applies. 
5.2. Exclusion Criteria Update d exclusion criterion #19 
to clarify  that parti cipants m ust be 
willing to stop alcoho l 
consumption for 48 hours (rather 
than 24 hours) pri or to admissio n.Minor change to clarify an 
inconsistency in the original 
protocol .
6.1.1. Administration 
DetailsAdded language to instruct that 
pirtobrutinib bedosed at the sam e 
time as rosuvastatin or no more 
than 15 minutes beforehand.To provi de clarificat ion to the 
site.
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
4Table of Contents
1. Protocol Summary ...................................................................................................... 7
1.1. Synopsis ....................................................................................................................... 7
1.2. Schema ......................................................................................................................... 9
1.3. Schedule of Act ivities (SoA) ...................................................................................... 10
2. Introduction .............................................................................................................. 13
2.1. Study  Rati onale .......................................................................................................... 13
2.2. Background ................................................................................................................ 13
2.3. Benefit/Risk Assessment ............................................................................................ 14
3. O bjectives and Endpoints ......................................................................................... 16
4. Study Design ............................................................................................................. 17
4.1. Overall Design ............................................................................................................ 17
4.2. Scientific Rati onale f or Study  Design ......................................................................... 17
4.3. Justification for Dose .................................................................................................. 18
4.4. End of Study  Definit ion.............................................................................................. 18
5. Study Population ...................................................................................................... 19
5.1. Inclusio n Cri teria........................................................................................................ 19
5.2. Exclusio n Cri teria....................................................................................................... 20
5.2.1. Rationale for Exclusio n of Certain Study  Parti cipants ................................................. 21
5.3. Lifest yle Considerat ions............................................................................................. 22
5.3.1. Meals and Dietary  Restri ctions................................................................................... 22
5.3.2. Substance Use: Caffeine, Alcohol, and Tobacco ......................................................... 22
5.3.3. Activity...................................................................................................................... 22
5.4. Screen Failures ........................................................................................................... 22
6. Study Interventions and Concomitant Therapy ...................................................... 23
6.1. Study  Intervent ions Administered ............................................................................... 23
6.1.1. Administrati on Details ................................................................................................ 23
6.2. Preparati on, Handling, Storage, and Accountabilit y.................................................... 23
6.3. Measures to Minimize Bias: Rando mizat ion and Blinding .......................................... 24
6.4. Study  Intervent ion Compliance ................................................................................... 24
6.5. Dose Modificat ion...................................................................................................... 24
6.6. Continued Access to Study  Intervent ion after the End of the 
Study .......................................................................................................................... 24
6.7. Treatment of Overdose ............................................................................................... 24
6.8. Concomitant Therapy .................................................................................................25
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 26
7.1. Discontinuati on of  Study  Intervent ion........................................................................ 26
7.1.1. Hepati c Cri teria f or Di scontinuati on........................................................................... 26
7.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. 26
7.3. Lost to Follow -Up...................................................................................................... 27
8. Study Assessments and Procedures ......................................................................... 28
8.1. Efficacy Assessments .................................................................................................28
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
58.2. Safety Assessments .................................................................................................... 28
8.2.1. Physical Examinat ions................................................................................................ 28
8.2.2. Height and Wei ght...................................................................................................... 29
8.2.3. Vital Signs.................................................................................................................. 29
8.2.4. Electrocardiograms ..................................................................................................... 29
8.2.5. Clinical Laboratory  Tests ............................................................................................ 29
8.2.6. Pregnancy Testing ...................................................................................................... 30
8.2.7. S afety Moni toring ....................................................................................................... 30
8.3. Adverse Events, Serious Adverse Events, and Product 
Com plaint s................................................................................................................. 32
8.3.1. Timing and Mechanism for Collect ing Events ............................................................ 33
8.3.2. Pregnancy ................................................................................................................... 34
8.4. Pharmacokinet ics........................................................................................................ 35
8.4.1. Bioanalysis ................................................................................................................. 35
8.5. Pharmacodynamics ..................................................................................................... 35
8.6. Genet ics..................................................................................................................... 35
8.7. Biomarkers ................................................................................................................. 35
8.8. Immunogenicit y Assessments ..................................................................................... 35
8.9. Heal th Economics ....................................................................................................... 35
9. Statistical Considerations ......................................................................................... 36
9.1. Statistical Hypotheses .................................................................................................36
9.2. Analyses Sets ............................................................................................................. 36
9.2.1. Study  Parti cipant Disposit ion...................................................................................... 36
9.2.2. Study  Parti cipant Characterist ics................................................................................. 36
9.3. Statistical Analyses ..................................................................................................... 36
9.3.1. Pharmacokinet ic Analyses .......................................................................................... 37
9.3.2. Safety Analyses .......................................................................................................... 37
9.4. Interim Analysis ......................................................................................................... 38
9.5. Sample Si ze Determinat ion......................................................................................... 38
10. Supporting Documentation and Operational Considerations ................................ 39
10.1. Appendix 1: Regulatory , Ethical , and Study  Oversight 
Considerations ............................................................................................................ 39
10.1.1. Regulatory  and Ethi cal Considerat ions........................................................................ 39
10.1.2. Inform ed Consent Process .......................................................................................... 39
10.1.3. Data Protection ........................................................................................................... 40
10.1.4. Disseminat ion of Clinical Study  Data ......................................................................... 40
10.1.5. Data Qualit y Assurance .............................................................................................. 41
10.1.6. Source Documents ................................ ...................................................................... 42
10.1.7. Study  and Si te Start and Cl osure ................................................................................. 42
10.1.8. Publicat ion Policy ....................................................................................................... 43
10.2. Appendix 2: Clinical Laboratory  Tests ........................................................................ 44
10.2.1. Blood Sam pling Summary .......................................................................................... 46
10.3. Appendix 3: Adverse Events and Serious Adverse Events: 
Definit ions and Procedures for Recording, Evaluating, Fo llow-
up, and Reporting ....................................................................................................... 47
10.3.1. Definit ion of Adverse Event ....................................................................................... 47
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
610.3.2. Definit ion of Serious Adverse Event ........................................................................... 48
10.3.3. Definit ion of Product Complaint s............................................................................... 49
10.3.4. Recording and Fo llow-Up of AE and/or SAE and Product 
Com plaint s................................................................................................................. 49
10.3.5. Reporting of Serious Adverse Events .......................................................................... 51
10.3.6. Regulatory  Reporting Requirements ................................
........................................... 51
10.4. Appendix 4: Contraceptive and Barrier Guidance ....................................................... 53
10.4.1. Definit ions.................................................................................................................. 53
10.4.2. Contra ception Guidance .............................................................................................. 53
10.4.3. Contraception Methods ............................................................................................... 54
10.5. Appendix 5: Genetics .................................................................................................56
10.6. Appendix 6: Liver Safet y: Suggested Actions and Follow -up 
Assessments ............................................................................................................... 57
10.7. Appendix 7: Abbreviat ions......................................................................................... 59
11. References ................................................................................................................. 61
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
71. Protocol Summary
1.1. Synopsis
Protocol Title:
A Phase 1, Open -Label, Drug Interacti on Study  to Invest igate the Effect of Single and Mult iple 
Doses of Pi rtobruti nib on the Pharmacokinet ics of Rosuvastatin in Healthy Participants
Brief Title:
A drug interaction study  invest igating the effect of pirtobrutinib on the pharmacokinet ics of 
rosuvastatin.
Rationale :
The breast cancer resistance protein (BCRP) is a membrane -bound transporter located in the 
gastrointestinal tract, liver, kidney, brain endothelium, mammary  tissue, testis, and placenta, 
responsible for ex porting a wide range o f substrates across bio logical membranes. Certain 
substrates of BCRP have been shown to have clinically significa nt drug interactions when 
administered with inhibitors of BCRP. 
Rosuvastatin is a commo nly used index substrate for BCRP (FDA, 2021). Pirtobrutinib is an 
inhibitor of BCRP in vitro. Therefore, this study  aims to invest igate a potential drug- drug 
interact ion by evaluat ing the pharmacokinet ics (PK), safet y, and tol erabilit y of rosuvastatin in 
the presence o f pirtobrutinib .
Objectives andEndpoint s:
Object ives Endpoints
Primary
To evaluate the effect of single and 
multiple doses of pirtobrutinib on 
BCRP activit y in healthy partici pantsCmaxand AUC(0 -∞) of rosuvastatin
Secondary
To evaluate the safet y and tol erabili ty 
of rosuvastatin in co mbinat ion with 
pirtobrutinib in healt hy part icipants. Incidence of TEAEs and SAEs
Abbreviations: AUC(0 -∞)=area under the concentration versus time curve from time zero to infinity; 
BCRP =breast cancer resistance protein; C max=maximum observed drug concentration; SAE = serious adverse 
event; TEAE =treatment -emergent adverse event.  
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
8Overall Design
Brief Summary:
Study  J2N-MC-JZNW (JZNW) is a Phase 1, open -label, drug interaction study evaluat ing the 
effect of single and mult iple doses of pirtobrutinib on the PK, safet y, and tol erabilit y of 
rosuvastatin. 
Number of Participants:
Approximately  36participants will be enrolled to ensure that at least 28evaluable participants 
complete the study .
Intervention Groups and Duration :
All participants will be screened within 42days prior to enrollment. Eligible participants will be 
admitted to the clinical research unit (CRU) on Day  -1 and rem ain resident in the CRU until 
discharge on Day  18. A follow -up visi t will  be perform ed 7 (±2) days after the last dose of study 
intervent ion. 
Parti cipants will receive the following study  intervent ionwhile resident in the CRU:
Day 1: 20 m g rosuvastatin alone
Day 6: 20 m g rosuvastatin co -administered with 200 mg pirtobrutinib
Days 7 to 12: once daily ( QD) doses of 200 mg pirtobrutinib alo ne 
Day 13: 20 m g rosuvastatin co -administered with 200 mg pirtobrutinib
Days 14 to 17: QD doses of 200 mg pirtobrutinib alo ne.
Data Monitoring Committee: No
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
91.2. Schema
Abbreviations: CRU = clinical research un it; QD = once daily. 

CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
101.3. Schedule of Activities (SoA)
Study Procedure
Screening
(D-42 to -2)Treatment Period (Study Days) FU/
EDb
-1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 a24
(±2
days)
Informed consent X
Admission to 
CRUX
Discharge from 
CRUX
Outpatient visit X X
Medical history 
and demographicsX
Participant 
eligibilityX X
Rosuvastatin
administrationX X X
Pirtobrutinib 
administrationX X X X X X X X X X X X
Height X
Weight X
Pregnancy test c X X X
Urine drug screen 
(including 
cotinine)X X
Ethanol test X
Supine vital signs 
(PRand BP)dX P, 2h24 
hP, 2h24 
hP, 2h24 
hX X
Oral body 
temperatureX
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
11Study Procedure
Screening
(D-42 to -2)Treatment Period (Study Days) FU/
EDb
-1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 a24
(±2
days)
12-lead ECG X P X P X P X X X
Clinical 
laborato ry testsX P X P X P X X X
Physical 
examination eX X X
Genetic blood 
sample for 
screeningX
Rosuvastatin PK 
sampl esgP, 0.5, 
1, 1.5, 
2, 2.5, 
3, 4, 5, 
6, 8, 
12 h24 
h48 
h72 
h96 
hPf, 0.5, 
1, 1.5, 
2, 2.5, 
3, 4, 5, 
6, 8, 
12 h24 
h48 
h72 
h96 
h120 
hP, 0.5, 
1, 1.5, 
2, 2.5, 
3, 4, 5, 
6, 8, 
12 h24 
h48 
h72 
h96 
h120 
h
Adverse event 
reviewX X X X X X X X X X X X X X X X X X X X X
Concomitant 
medication reviewX X X X X X X X X X X X X X X X X X X X X
CCI
CCI
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
12Abbreviations: BP=blood pressure; CRU = clinical research unit; D =day; ECG = electrocardiogram; ED =early  discontinuation; FU = follow -up; h =hours 
postdose; P = predose; PK =pharmacokinetic(s); PR=pulse rate .  
aParticipants will be discharged from the CRU on Day 18once all study procedures are completed. 
bParticipants will attend a n outpatient follow -up visit 7 (± 2) days after the final dose of study intervention. If participants are not able to attend the CRU for 
this visit, the CRU should contact the participant via phone call to conduct adverse event and concomitant medication review .If applicable, ED assessments 
should be performed on the day of discontinuation (or as close to it as possible).
cFemale participants only. Serum pregnancy test at screening and urine pregnancy test at all other times.
eComplete physical examination at check -in,discharge from CRU , and follow -up. Additio nal sy mptom -driven physical examinations may be performed at the 
discretio n of the invest igator. 
CCI
CCI
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
132. Introduction
2.1. Study Rationale
The breast cancer resistance protein (BCRP) is a membrane -bound transporte rlocated in the 
gastrointestinal tract, liver, kidney, brain endothelium , mammary  tissue, t estis, and placenta , 
responsible for exporting a wide range o f substrates across bio logical membranes .Certain 
substrates of BCRP have been shown to have clinically significant drug interacti ons when 
administered with inhibitors of BCRP (Internat ional Transporter Consorti umet al. 2010) . 
Rosuvastatin is a commo nly used index substrate for BCRP (FDA
, 2021). Pirtobruti nibis an 
inhibitor of BCRP in vitro , with a half maximal inhibitor y concentrati on of 18 
µM. Therefore, 
this study  aims to invest igate a potential drug-drug interaction (DDI) by evaluat ingthe 
pharmacokinet ics (PK), safet y, and tol erabili ty of rosuvastatin in the presence of pirtobrutinib.
2.2. Background
Pirtobrutinib is a select ive inhibitor of the Bruton’s tyrosine kinase ( BTK) . BTK i s a key  
component of the B -cell receptor signaling complex and plays a crit ical ro le in the proliferat ion 
and survival o f diverse B cell malignancies. Pirtobrutinib is a sma ll molecule designed to block 
the adenosine triphosphate binding site of the BTK kinase co mpet itively.
Pirtobrutinib is currently being studied in an ongoing first-in-human study  (LOXO -BTK -18001),
in patients with previ ously  treated chronic lymphocyt ic leukemia/ small lymphocy tic leukemia, or
non-Hodgkin’s lympho ma.Pirtobrutinib is also being studied in threePhase 3 studies in pat ients 
with hematol ogical malignancies. In addit ion, pirtobrutinib has been invest igated in twelve 
Phase 1 studi es in heal thy participants and participants with renal impairment . One of these 
studi es in partici pants wi th hepatic impairment and match edhealthy control s is ongoing . 
As of a data cutoff date of September 27, 2020, safety  data were available fro m a total  of 
324patients treated in Study  LOXO -BTK -18001, wi th monotherapy  doses ranging fro m 
25to300mg once daily  (QD
).
From  the available safet y data a cross the 324 pati ents in the first -in-human study  
(LOXO- BTK -18001):
the treatm ent-emergent adverse events ( TEAEs )reported in ≥10% of patients were
ofatigue (20.1% total, 8.3% considered related to study drug) 
odiarrhea (17.0% total, 8.6% considered related to study  drug) 
ocontusion (13.0% total, 9.0% considered related to study drug). 
TEAEs considered related to study  drug were reported in 156 of 324 patients (48.1%) 
TEAEs of severit y Grade 3 or 4 were reported in 87 of 324 patients (26.9%), with 
41(12.7%) of these Grade 3 or 4 TEAEs reported as related to study drug
On-study  death (death w ithin 28 days of the last dose of study  drug) due to a Grade 5 
(fatal) adverse event ( AE)was reported in 4 of 324 patients (1.2%)
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
14One Grade 5 AE, Enterococcus faecium -related septic shock, was considered related to 
study  drug. All other Grade 5 AEs were c onsidered to be not rel ated to study  drug; these 
included pneumo nia fungal, shock, and pleural effusion.
Across the Phase 1 studies, p irtobrutinib has been administered to a total of 184healt hy 
participants (at the time o f this protocol’s development) at single doses from 200 to 900 mg and 
multiple doses of 200 mg for a maximum o f 14 days. 
From  the available safet y data in Phase 1 studies, t reatm ent-related TEAEs have been reported in 
30 (16%) healthy participants . The most frequent lyreported treatment -related TEAEs were 
petechiae and headache. The m ajority of treatm ent-related TEAEs were Grade 1 (mild) in 
severit y and a ll AEs had resolved by the end of study. 
As part of each clinical study conducted in patients or heal thyparticipants, electrocardi ogram  
(ECG )and vital signs are performed at intervals specified by the protocol. For study 
LOXO -BTK -18001 conducted in pat ients, no clinically significant findings of corrected QT 
interval  (QTc)prolongati on have been i dentified in the 330patients as of September 27, 2020. In 
addition,
there have been no clinically significant abnorm al findings in vi tal signs and ECG data 
in the studies invest igating pirtobrutinib conducted in healt hy participants to date. 
Preliminary data a fter oral  adm inistration o f single doses of pirtobrutinib ranging fro m 25to 
300mgQDsuggest the median time to maximum drug concentration ( tmax)isapproximately  
2hours ,the terminal half-life ( t1/2)isapproximately 20hours , and the PK is dose proporti onal.
2.3. Benefit/Risk Assessment
The 200 m g QD dose of pirtobrutinib administered in this study  is not anti cipated to induce any  
potenti al risk to parti cipants as the dose does not exceed the highest dose safely administered in
theclinical studies in pat ients or healthy partici pants. This dose and dosing regimen were
selected as theyrepresent the recommended phase 2 dose (RP2D) based on the PK, safet y, and 
antitumor activit y observed in the Phase 1/2 study  (Study  LOXO -BTK -18001) . In pati ents, 
pirtobrutinib has demonstrated a safe and tolerable profile across all doses tested (25 to 300 mg 
QD). No dose-limiting toxicit ies occurred in Study LOXO -BTK -18001, and no maximum 
tolerated dose was i dentified. No clinically  significant safet y or tol erabilit y concerns have been 
ident ified in healthy participants to date for pirtobrutinib up to the highest single dose of 900 mg 
and mult iple dose sof 200 mg for up to 14 days. 
There i s no antici pated therapeuti c benefi t for the parti cipants in thi s study . However, 
participants may benefit fro m the screening procedures (through detection of unknown healt h 
issues) even if they  receive no therapeuti c benefi t from  the study .
More detailed informat ion about the known and expected benefits and risks of pirtobrutinib may 
be found in t he Invest igator’s Brochure .
Rosuvastatin is a commo nly used drug in DDI studies and the dosing regimen in the current 
study  (20 mg) is consistent with the prescribing recommendat ions. The m ost frequen t (≥2%) 
adverse reactions fo llowing rosuvastatin dosing are headache, myalgia, abdo minal pain, asthenia, 
and nausea. Cases of myopathy and rhabdo myolysis have been reported with rosuvastatin. These 
risks can occur at any  dose l evel, but are increased at the hi ghest dose of 40 mg. The incidence o f 
rhabdo myolysis is 0.3to 13.5 cases per 1,000,000 (Mendes et al . 2014). During the current 
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
15study , participants shoul d prom ptly report an y unexplained muscle pain, tenderness, or 
weakness. Elevations in liver enzymes (alanine aminotransferase [A LT] and aspartate 
aminotransferase [AST]) have been reported following rosuvastatin dosing. In m ost cases ,the 
elevations were transient and resolved or improved on continued dosing or after brief 
interrupti on of  dosing. In the cu rrent study , blood sam ples to determine liver enzyme s(as part of 
clinical laboratory  tests) will be collected prior to each dosing occasi on of rosuvastatin .
More detailed informat ion about the known and expected be nefits and risk o f rosuvastatin may 
be found in the prescribing informat ion (Crestor ®Prescribing Informat ion, 2020). 
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
163. Objectives and Endpoints
Object ives Endpoints
Primary
To evaluate the effect ofsingle and 
multiple doses of pirtobrutinib on BCRP 
activit y in healt hy participantsCmaxand AUC (0-∞)of 
rosuvastatin
Secondary
To evaluate the safet y and tol erabili ty of 
rosuvastatin in co mbination wit h 
pirtobrutinib in healt hy part icipants Incidence of TEAEs and SAEs
Abbreviations: AUC(0 -∞)=area under the concentration versus time curve from time zero to infinity; 
BCRP =breast cancer resistance protein; Cmax=maximum observed drug concentration; SAE = serious adverse 
event; TEAE =treatment -emergent adverse event. 
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
174. Study Design
4.1. Overall Design
Study  J2N-MC-JZNW is a Phase 1, fixed sequence, open -label study  in healt hy participants that 
will invest igate the effect of single and mult iple doses of pirtobrutinib on the PK of rosuvastatin. 
The schema in Sect ion 1.2illustrates the study  design.
Approximately  36participants will be enrolled to ensure that at least 28evaluable participants 
complete the study . 
Screening
All participants will be screened for study  inclusio n within 42days pri or to enro llment (Day  1).
Screening should not occur less than 14 day s prior to enro llment (Day  1), in order to allow 
sufficient time to receive genoty ping resul ts. 
Treatment and Assessment Period
Parti cipants will check in to the clinical research unit (CRU) on Day  -1 and remain resident until 
discharge on Day  18. 
While resident at the CRU, a ll participants will receive study  intervent ionas fo llows:
Day 1: 20 m g rosuvastatin alone
Day 6: 20 m g rosuvastatin co -administered with 200 m g pirtobrutinib
Days 7 to 12: QD doses of 200 m g pirtobrutinib alone 
Day 13: 20 m g rosuvastatin co -administered with 200 m g pirtobrutinib
Days 14 to 17: QD doses of 200 m g pirtobrutinib alo ne.
PKblood sam pling and s afety assessments, including vital signs measurements, physical 
examinat ions, clinical laboratory  tests, ECGs, and AE recording, will be performed according to 
the Schedule of Activities(SoA; Section 1.3).
Parti cipants will be discharged from the CRU on Day  
18following com pletion of study
procedures, provided they  are deemed medically  fit by  the invest igator or designee .
Follow -Up
Parti cipants will attend an outpatient fo llow-up visi t 7(± 2) days after the final dose of study  
intervent ion. If parti cipants are not able to attend the CRU for this visit, the CRU shoul d contact 
the participant via phone call to conduct AE and concomitant medicat ion revi ew.
4.2. Scientific Rationale for Study Design
In order to allow each subject to act as their own control for safet y and PK co mpar isons, a fixed 
sequence design has been selected. 
This study  will be open label as the study primary endpo int PK m easures are objective rather 
than subject ive.
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
18Based on the t 1/2of rosuvastatin (19hours; Crestor ®Prescribing Informat ion, 20 20), a period of 
4 to5days between rosuvastatin doses is considered sufficient time for the study  intervent ionto 
washout. Based on the PK profile of pirtobrutinib, QD dosing for 7 day s is considered sufficient 
time for pirtobrutinib to reach steady  state. 
The PK of rosuvastatin will be evaluated after a single pirtobrutinib dose on Day  6 to assess the 
effect on intestinal BC RP and after multiple pirtobrutinib doses on Day  13to assess the effect on 
systemic BCRP . 
Conducting the study  in healt hy part icipants mit igates the potential confounding effects of the
disease state , other medical condit ions, and concomi tant m edicati ons in patients.
4.3. Justification for Dose
Pirtobrutinib 200 mg QD is the chosen recommended Phase 2 dose for the ongoing global 
Phase 1/2first-in-human study  (LOXO -BTK -18001) in patients previously  treated for chronic 
lymphocy tic leukemia/small lymphocy tic leukemia or non-Hodgki n’s lympho ma. Previous 
clinical data in healt hy participants demonstrate that pi rtobruti nib is safe and well tolerated at 
doses of 200 mg QD with no dose -limit ing toxicit ies identified in humans. 
Rosuvastatin is a commo nly used drug in DDI studi es. The dosing regime nof rosuvastatin
(20mg)in the current study  is consistent with the prescribing recommendations. 
4.4. End of Study Definition
The end o f the study  is defined as the dat e of the last scheduled procedure shown in the SoA
(Secti on 1.3)for the last participant in the study .
A participant is considered to have co mpleted the study  if the part icipant has completed the 
treatm entperiod of the study  andfollow-up procedures as shown in the SoA (Sectio n 1.3).
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
195. Study Population
Eligibilit y of parti cipants for enrollment in the study will be based on the results of screening 
medical history , vital signs, clinical laboratory  tests ,and ECG , and physical examinat ion at 
check -in (Day -1). The nature of any condit ions present at the time of the physical examinat ion 
and any  pre-exist ingcondi tions will be documented.
Screening may occur up to 42 days prior to enrollment. Eligible participants who are not enrolled 
within 42days o f screening may undergo an additional medical assessment and/or clinical 
measurements to confirm their elig ibilit y. In such instances, repeat the fo llowing tests and 
procedures: weight, vital signs, ECG, clinical laboratory  tests, physical examinat ion, and 
pregnancy test (females only). Any other procedures may be repeated at the discretion o f the 
investigator.
The inclusio n and exclusio n criteria used to determine eligibilit y shoul d be applied at screening 
only, unless otherwise specified, and not continuously throughout the study .
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is not permitted.
5.1. Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criter ia apply:
Participant Characteristics
1.Are male s,or female s not of childbearing potential
a.Reproductive definit ions and contraception requirements are provided in 
Appendix 4 (Secti on 10.4).
2.Are between 18 and 64years of age inclusive, at the time of signing the informed 
consent.
3.Have a body  mass index of 18.0to 32.0 kg/m2(inclusive) and a body  weight of at l east 
50 kg.
4.Areovertly healt hy as determined by medical evaluation including medical history ,
physical examinat ion(at check -in/Day -
1), vital signs, and ECG . 
5. H ave clinical laboratory  test resul ts wi thin norm al reference range for the populat ion or 
investigative site, or resul ts wi th acceptable deviat ions that are judged to be not clinically 
significant by  the invest igator , except for the follo wing parameters which must be within 
the specified ranges :
a.ALT and AST≤1.5 × upper limit of normal (ULN)
b.Total  bilirubin (TBL) ≤1.5 × ULN (isolated bilirubin >1.5 × ULN is acceptable if 
TBL is fractionated and direct bilirubin is <35%). 
6. Have venous access sufficient to allow for blood sampling as per protocol. 
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
20Informed Consent
7.Capable of giving signed informed consent as descri bed in Appendix 1 (Secti on 10.1),
which includes co mpliance wit h the requirements and restrictions listed in the informed 
consent form (ICF) and in this protocol .
5.2. Exclusion Criteria
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply:
Medical Conditions
1.Have k nown allergies to pirtobrutinib or rosuvastatin , related com pounds, or any  
components of the formulat ion.
2.Have an abnormal blood pressure and/or pulse rate, deemed to be clinically significant by 
the invest igator.
3.Have a significant history  of or current c ardiovascular, respiratory , hepatic, renal, 
gastrointestinal, endocrine, hematological, neurological , or psy chiatric disorder or 
surgery  (including cholecystectomy) capable of significant ly altering the absorption, 
metabo lism, or eliminat ion of drugs; of c onstituting a ri sk when taking the invest igational 
product; or of interfering wit h the interpretation of data.
a.Note: history o f unco mplicated appendectomy will be allowed.
4.Have had lympho ma, leukemia, or any  malignancy within the past 5 y ears except for 
basal cell or squam ous epi thelial carcino mas of the skin that have been resected with no 
evidence of metastatic disease for 3 y ears.
Prior/Concomitant Therapy
5.Have used or intend to use prescript ion or nonprescript ion medication (including dietary  
supplements, vitamins, and/or herbal medicat ions), or modulators of CYP3A4 or BCRP
within 7 days pri or to dosing, unless, in the opinio n of the invest igator and sponsor, the 
medica tion will not interfere with the study .
6.Vaccinat ion with live vaccines with in 28 days prior to screening, or plans to receive such 
vaccines during the study .
a.Note: use of non -live (inact ivated) vaccinations will be allowed.
Prior/Concurrent Clinical Study Experience
7.Are current ly enrolled in any other clinical study  involving an invest igational product or 
any other ty pe of medical research judged not to be scient ifically or medically co mpat ible 
with this study .
8.Have participated, within the last 30 days, i n a clinical study  involving an invest igational 
product. If the previous invest igational product has a long half -life, 5 half -lives or 
30days (whichever i s longer) shoul d have passed.
9.Have previously co mpleted or withdrawn fro m this study  or any  other study  invest igating 
pirtobrutinib (also known as LOXO -305).
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
21Diagnostic A ssessments
10.Show evidence of human immunodeficiency virus (HIV) infection and/or posit ive human 
HIV antibodies .
11.Show evidence of hepat itis C and/or posit ive hepatit is C antibody .
12.Show evidence of hepat itis B and/or posit ive hepatit is B surface ant igen.
Other Exclusions
13.Have c.34AA, c.421AA, or c.34GA/421CA genotypes of ABCG2 as determined through 
genoty ping.
14.Have c.521TC and c/521CC genoty pes of  SLCO1B1 as determined by genoty ping. 
15.Are females who are lactating or have a posit ive pregnancy test.
16.Regularly use known drugs of abuse or show positive findings on drug screening .
17.Have donated blood of more than 500 mL within the previous 3months of study  
screening .
18.Have an average weekly  alcoho l intake that exceeds 21 units per week (males) and 
14units per week (females) . If calculation of units is required, usethe following
equation: Number of units =[total  volume of drink (mL) ×ABV (%)]/1000 , where ABV 
is alcoho l by vo lume.
19.Are unwilling to stop alcoho l consumpt ion 48hours prior to admissio n and while resident 
at the CRU.  
20.Use of tobacco -or nicotine -containing products wit hin 1month prior to check -in, or 
positive cotinine test at screening or check -in.
21.Are invest igative site personnel direct ly affiliated with this study  and/or thei r immediate 
families. Immediate family  is defined as a spouse, bio logical  or legal  guardian, child, or 
sibling.
22.Are Lilly  or Labcorp employees.
23.In the opinion o f the invest igator or sponsor, are unsuitable for inclusio n in the study .  
5.2.1. Rationale for Exclusion of Certain Study Participants
The human BCRP transporter (also known as ABCG2) is polymorphic. Parti cipants with the 
c.34AA, c.421AA, and c.34GA/421CA genoty pes will  be excluded because these genet ic 
polymorphisms are associated with impaired BCRP activit y (Furukawa et al. 2009, Wan et al. 
2015, Keskitalo et al. 2009). Because the ac tivity of BCRP is impaired with these participants , it 
woul d be ant icipated that even complete inhibit ion of BCRP would not result in a substant ial 
change in rosuvastatin exposure. Accordingly, excluding participants with these polymorphisms 
will ensure th at the “worst -case” interaction between pirtobrutinib and rosuvastatin will be 
evaluated in this study .
The human OATP1B1 transporter (also known as SLCO1B1) is also polymorphic. In order to 
evaluate worst -case interactions between pirtobrutinib and rosuva statin, participants with the 
c.521TC and c/521CC genoty pes will be excluded fro m this study  because this genet ic 
polymorphism is associated with decreased transporting act ivity of OATP1B1 (Ni emi et al . 
2011) and higher plasma rosuvastatin concentrations ( Crestor ®Prescribing Informat ion, 2020).  
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
225.3. Lifestyle Considerations
Throughout the study , parti cipants m ay undergo medi cal assessments and review of compliance 
with requi rements before continuing in the study .
5.3.1. Meals and Dietary Restrictions
While resident in the CRU, participants will consume only food and beverages that are provided 
to them by  the CRU staff. Standard meals (breakfast, lunch, dinner, and snack) will be provided 
to the parti cipants while resident at the CRU.
Rosuvastatin and pi rtobrutinib will be administered after an overnight fast of at least 8 hours on 
Days 1, 6, and 13 . On these days, p articipants will rem ain fasted for approximately 4 hours 
postdose, at which time a meal will be served. Water is permitted ad libitum during the fast ing 
period, except for 1 hour before and after dose administration (other than the water provided 
during dosing ).On all other dosing days ( i.e., pirtobrutinib alo neon Days 7 to 12 and 14 to 17), 
there are no fastin g requi rements for dosing.
Parti cipants will refrain from  consumpti on of  grapefrui t or grapefrui t juice f rom 7 days before 
the start of study  intervent ion unt il after the final  PK sample collect ion.
5.3.2. Substance Use: Caffeine, Alcohol, and Tobacco
Participants will abstain fro m ingest ing caffeine -or xanthine -containing products ( e.g., coffee, 
tea, cola drinks ,
and chocolate) for 48 hours prior to check- in unt il discharge from the CRU. 
Participants will abstain fro m alcoho l for 48hours prior to check -in until discharge from  the 
CRU .
Parti cipants will not be permitted to use tobacco -or nicotine -containing products within 1month 
prior to check -in until the fo llow-up visit. 
5.3.3. Activity
Parti cipants will abstain fro m strenuous exercise for 48 hours before each blood collect ion for 
clinical laboratory  tests.Participant s may parti cipate i n light recreational act ivities during the 
study (e.g., watch ingtelevisio n, read ing).
5.4. Screen Failures
A screen failure occurs when a participant who consent sto parti cipate in the clinical study isnot 
subsequent ly enrolled in the study .
Individuals who do not meet the criteria for participation in this study  (screen failure) maybe 
rescreened. There m ust be at l east 2 weeks between the screen failure and the new screening.
Rescreened participants should be assigned a new parti cipant number for the rescreening event. 
If applicable, participants may be re
-tested up to 1 time at the discret ion of the invest igator (e.g., 
abnorm al laboratory  resul t) bef ore being deemed a screen failure.
Eligible participants who are not enrolled within 42days of screening may  undergo an addi tional 
medical assessment and/or clinical measurements to confirm their eligibilit y; see Section 5for a 
list of required assessments in these cases.
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 N -M C -J Z N W (a) 
2 3 6. St u d y I nter ve nti o n s a n d C o nc o mit a nt T her a p y 
St u d y  i nt er ve nt i o n is defi ne d as a n y i n vest i gat i o nal i nt er ve nt i o n(s) or mar kete d pr o d uct(s), 
i nt e n de d t o be a d mi nistere d t o / use d b y a st u d y  partici pa nt acc or di n g t o t he st u d y  pr ot oc ol .
6. 1. St u d y I nter ve nti o ns A d mi nistere d 
T his st u d y  i n v o l ves t he c o m paris o n of r os u vastati n a d mi nistere d al o ne a n d r os u vastati n 
c o -a d mi nistere d wit h pirt o br uti ni b . Ta ble J Z N W . 1 s h o ws t he st u d y  i nt er ve nti o ns t o be 
a d mi nistere d. 
T a ble J Z N W . 1 St u d y I nter ve nti o ns A d mi nistere d 
St u d y I nter ve nti o n R os u vastati n Pirt o br uti ni b 
D os a ge F or m ul ati o n Ta blet Ta blet 
U nit D ose Stre n gt h/ D os a ge Le vel 2 ×1 0- m g ta blets 
( 2 0 -m g d ose) 2 ×1 0 0- m g ta blets 
( 2 0 0- m g d ose) 
R o ute of A d mi nistr ati o n Oral Oral 
D osi n g I nstr ucti o ns 2 ta blets a d mi nistere d al o ne o n 
Da y 1 a n d wit h pirt o br uti ni b o n 
Da ys 6 a n d 1 3 2 ta blets a d mi nistere d wit h 
r o s u vastati n o n Da ys 6 a n d 1 3, a n d 
al o ne o n D a y s 7 t o 1 2 a n d 1 4 t o 1 7 
6. 1. 1. A d mi nistr ati o n Det ails 
Eac h d ose of r os u vastati n a n d pi rt o br uti ni b will be a d m i nistere d orall y wi t h  a p pr o xi matel y 
2 4 0 m L of r o o m te m perat ure water i n t he m or ni n g of eac h d osi n g da y (see Sect i o n 1. 3 )i n a 
si tti n g p osi ti o n. W he n r os u vastati n a n d pi rt o br uti ni b are a d mi ni ster ed c o nc urre ntl y, 2 4 0 m L of 
r o o m  t e m perat ure water will be use d f or all ta blets a n d pir t o b r uti ni b s h o ul d be a d mi nister e d at 
t h e sa m e ti me as r os u vastati n or n o m ore t ha n 1 5 mi n utes pri or t o r os u vastati n. If  r e q ui re d t o 
c o m plete d osi n g, a d dit i o nal water m a y be gi ve n i n 5 0 m L ali q u ots a n d will be rec or de d i n t he 
s o urce b ut will n ot be c o nsi dere d as a pr ot oc ol de viat i o n. 
Par ti ci pa nts will n ot be all o we d t o lie s u pi ne f or 2 h o urs after d osi n g, u nless cli nicall y i n dicate d 
or f or st u d y  pr oce d ures. 
D oses of  r os u vastati n a n d pi rt o br uti ni b o n Da ys 1, 6, a n d 1 3 will be a d mi nistere d after a n 
o ver ni g ht fast of at least 8 h o urs a n d par ti ci pa nts will re mai n fast i n g f o r a p pr o xi matel y  4 h o urs 
p ost d ose. Water is per mitte d a d li bit u m d uri n g t he fast i n g p eri o d , e xce pt f or 1 h o ur bef ore a n d 
af ter d ose a d mi nistrati o n. O n all ot her d osi n g da ys (i.e., pirt o br uti ni b al o ne o n Da ys 7 t o 1 2 a n d 
1 4 t o 1 7), t here are n o fast i n g re q uire me nts f or d osi n g. 
6. 2. Pre p ar ati o n , H a n dli n g , St or a ge , a n d Acc o u nt a bilit y 
1. T he i n vest i gat or or desi g nee m ust c o nfir m a p pr o priate st ora ge c o n diti o ns ha ve bee n 
mai ntai ne d d uri n g tra nsit f or all st u d y  i nt er ve nt i o n recei ve d a n d a n y discre pa ncies are 
re p orte d a n d res ol ve d bef ore use of t he st u d y  i nt er ve nt i o n. 
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
242.Only participants enro lled in the study  may receive study  intervent ion. Only authori zed 
study  personnel may supply , prepare, or administer study  intervent ion. All study  
intervent ion must be stored in a secure, environmentally controlled, and mo nitored 
(manual  or autom ated) area i n accordance with the labeled storage condit ions wit h access 
limited to the investigator and authorized study  personnel .
3.The invest igator or authori zed study  personnel are responsible for study  interventi on 
accountabilit y, reconciliat ion, and record maintenance (i .e., recei pt, reconciliat ion, and 
final disposit ion records).
4.The invest igator or designee will return all unused study intervention to Lilly or its 
designee at the end of the study . Note: In some cases, sites may destroy  the m aterial if, 
during the invest igative site select ion, the evaluator has verified and documented that the 
site has appropri ate facilit ies and written procedures to dispose of clinical materials .
6.3. Measures to Minimize Bias: Randomization and Blinding
This is a non -rando mized, open -label study . 
6.4. Study Intervention Compliance
Parti cipants will be dosed at the CRU and they  will be administered study  intervent ion under 
medical superv ision by the invest igator or designee. The dose of study intervent ion and study  
participant i dentificat ion will be confirmed prior to the time of dosing. The date and time o f each 
dose administered will be recorded in the source documents and in the case r eport form ( CRF ).  
Study  site personnel  will examine each parti cipant’s m outh to ensure that the study  intervent ion 
was ingested.
6.5. Dose Modification
Dose m odificat ion is not permitted in this study .
6.6. Continued Access to Study Intervention after the End of t he Study
Pirtobrutinib or rosuvastatin will not be made available to participants after complet ion of the 
study .
6.7. Treatment of Overdose
For thi s study , any dose of pirtobrutinib greater than 200 mg or rosuvastatin greater than 20mg
within a calendar day will be considered an overdose.
The s ponsor does not recommend specific treatment for an overdose .
In the event of an overdose, the invest igator should :
Contact the Lilly clinical pharmacol ogist (CP)immediately.
Closely  monitor the parti cipant for any  AE/serious adverse event ( SAE )and laboratory 
abnorm alities 
Obtain a plasma sample for PK analysis if requested by  the Lilly  CP (determined on a 
case-
by-case basis).
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
25Docum ent the quanti ty of the excess dose in the CRF.
6.8. Concomitant Therapy
Any medicat ion or vaccine (including prescript ionor nonprescript ionmedication, dietary  
supplements, vitamins, and/or herbal medicat ions) that the participant is receiving at the time of 
enrollment or receives during the study must be recorded al ong wi th:
Reason for use
Dates of administration including start and end dates
Dosage information including dose and frequency for concomitant therapy  of special  
interest .
The Lilly CP shoul d be contacted if there are any questions regarding concomitant or prior 
therapy .
Parti cipants m ust abstain from  taking prescript ion or nonprescript ion drugs (including dietary  
supplements, vitamins ,and/orherbal medicat ions), or modulators of CYP3A4 or BCRP within 
7days prior to dosing until completion of the fo llow-up visit , unless,in the opinio n of the 
investigator and sponsor, the medication will not interfere with the study.
Parti cipants will not have received a live vaccine within 28 days prior to screening and will 
abstain from receiving such vaccines until completion of the follow-up visit . 
Acetaminophen is permitted for use at the discretion of the invest igator. If acetaminophen 
treatm ent is needed for pain management, the maximal allowed dose will be 3 g/day  from all 
acetaminophen -containing medicinal products. Other conco mitant m edicat ion may be considered 
on a case-by- case basis by the invest igator in consultation with the Lilly CP .
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
267. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
Parti cipants discont inuing from study intervent ionor from t he study prem aturely  for any reason 
shoul d com plete AE and other early discontinuat ion procedures as per the SoA (Section 1.3).
Discontinuati on of  specific sites or of the study  as a who le is described in Appendix 1
(Secti on10.1.7 ).
7.1. Discontinuation of Study Intervention
In rare instances, it may be necessary  for a participant to perm anent ly discont inue study  
intervent ion. If study  intervent ion is perm anent ly discontinue d, the pa rticipant willremain in the 
study  for appropriate safet y monitoring. See the S oA (Secti on 1.3)for data to be collected at the 
time of discont inuat ion of study  intervent ion and follow -up and for any  further evaluat ions that 
need to be com pleted.
7.1.1. Hepatic Criteria for Discontinuation
The study  intervent ionshoul d be discont inued if one or more of these condi tions occur: 
Elevation Exception
ALT or AST >5× ULN 
ALT or AST >3× ULN and either TBL >2× ULN or INR >1.5 In participants with Gilbert’s syndrome, 
doubling of direct bilirubin should be used 
for drug interruption or discontinuation 
decisions rather than TBL >2×ULN.
ALT or AST >3× ULN with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/o r eosinophilia (>5%)
ALP >3× ULN (when the source of increased ALP is the liver) 
ALP >2.5× ULN and TBL > 2× ULN In participants with Gilbert’s syndrome, 
doubling of direct bilirubin should be used 
for drug interruption or discontinuation 
decisions rather than TBL >2×ULN.
ALP >2.5 ×ULN with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/o r eosinophilia (>5%)
Source: FDA Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation, July 2009  
and other consensus guidelines with minor modifications
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase;
FDA =Food and Drug Administration; INR = international normalized ratio; TBL = total bili rubin; 
ULN =upper limit of normal.
Parti cipants who di scontinue from  study  intervent ion due to the abnormal liver tests will undergo
monitoring as described in Appendix 6(Secti on10.6).
7.2. Participant Discontinuation/ Withdrawal from the Study
A participant may withdraw from  the study :
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
27at any  time at the participant’s own request
at the request of the participant’s designee (for example, parents or legal guardian)
at the discretion of the invest igator for safet y, behavi oral, com pliance, or administrative 
reasons
if enro llment in any other clinical study invo lving an invest igational product or 
enrollment in any other type of  medical research judged not to be scient ifically or 
medically co mpat ible with this study
if the participant , for any  reason, requi res treatm ent wi th another therapeuti c agent that 
has been demonstrated to be effect ive for treatm ent of the study  indicat ion, 
discontinuat ion from the study  occurs pri or to introducti on of  the new agent .
Discontinuati on is expected to be uncommo n.
At the time of discont inuing from the study , if possible, an early discont inuat ion visit should be 
conducted, as shown in th e SoA(Secti on 1.3). See SoA for data to be collected at the time of 
study  discont inuat ion and fo llow-up and for any  further eval uations that need to be com pleted .
The participant will be permanently discont inued from both the study  interventi onand the study  
at that time .
If the participant withdraws consent for disclos ure of  future inform ation, the s ponsor m ay retain 
and cont inue to use any data co llected before such a withdrawal o f consent .If a participant
withdraws fro m the study , he/she may  request destructi on of  any sam ples taken and not tested ,
and the invest igator must document this in the site study records .
7.3. Lost to Follow -Up
A participant will be considered lost to follow -up if he/she repeatedly  fails to return for 
scheduled visits and is unable to be contacted by  the study  site. Si te personnel or desi gnee are 
expected to m ake diligent attempts to contact participants who fail to return for a scheduled visit 
or were otherwise unable to be fo llowed up by the site.
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
288. Study Assessments and Procedures
Study  procedures and their timing are summarized in the SoA (Secti on 1.3).
Immediate safet y concerns shoul d be discussed wit h the s ponsor immediately  upon occurrence or 
awareness to determine if the participant should cont inue or discont inue study  intervent ion.
Adherence to the study  design requi rements, including those specified in the SoA, is essent ial 
and required for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potenti al participant s 
meet all eligibilit y criteria. The invest igator will maintain a screening log to record details o f all 
participant s screened and to confirm eligibilit y or record reasons for sc reening failure, as 
applicable.
The specificat ions in this protocol for the t imings of safet y and sample co llection are given as 
targets to be achieved wit hin reasonable limits. Modificat ions may be made to the time po ints 
based upon emerging clinical informat ion. The scheduled t ime points may be subject to minor 
alterati ons; howev er, the actual  time m ust be correctly  recorded in the CRF.
Appendix 2 (Section 10.2)lists the laboratory tests that will be performed for this study.
Appendix 2 (Section 10.2.1 ) provides a summary of the maximum number and vo lume of 
invasive samples, for all sampling, during the study .
Unless otherwise stated i n subsect ions below, all samples collected for specified laboratory  tests 
will be destroy ed wi thin 60 days of receipt of confirmed test results. Certain samples may be 
retained for a longer period, if necessary , to com ply with applicable laws, regulat ions, or 
laboratory  certificati on standards.
8.1. Efficacy Assessments
Efficacy is not evaluated in this study . 
8.2. Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA (Section 1.3).
8.2.1. Physical Examinations
A co mplete physical examinat ion will be conducted as specified in the SoA (Secti on 1.3).
Com plete physical  examinat ions include, at a minimum, assessments of the following systems:
derm atological
head and eyes
ears, nose, mouth, and throat
pulmo nary
cardiovascular 
abdo minal
lymphat ic
musc uloskeletal /extremi ties
neurol ogical.
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
29Symptom -directed examinat ions may  be perform edas deemed appropriate by investigator. 
Any clinically  significant findings in a physical examinat ion shoul d be reported as AEs.
8.2.2. Height and Weight
Height and wei ght will  be measured and recorded at screening only (see SoA, Secti on 1.3).
8.2.3. Vital Signs
For each participant , vital signs m easurement s should be conducted according to the So A
(Secti on1.3).
Blood pressure and pulse rate should be measured after at least 5minutes in a supine posit ion.
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizzine ss or 
posture -induced symptoms. If orthostatic measurements are required, participants should be 
supine for at least 5 minutes and stand for at least 2minutes. If the participant feels unable to 
stand, supine vital signs only will be recorded. 
Oral body  temperature will be recorded at screening only . 
Addit ional vital signs may be m easured if warranted.
8.2.4. Electrocardiograms
For each participant, a single12 -lead digital ECG will be co llected according to the SoA 
(Secti on1.3). ECGs may be obtained at additional times, when deemed clinically necessary.
If scheduled at the same nominal t ime, ECGs must be recorded before collect ing any blood 
samples. Participants must be supine for approximately 5 to 10 minutes before ECG collect ion 
and remain supine but awake during ECG collect ion. All ECGs recorded should be stored at the 
investigat ional site.
ECGswill be interpreted by  a qualified physician (the invest igator or qualified designee) as soon 
after the tim e of ECG collect ion as possible, and ideally while the participant is st ill present, to 
determine whether the participant meets entry  criteria at the relevant visits and for immediate 
participant m anagement, shoul d any  clinically relevant findings be identified.  
If a clinically significant finding is ident ified (including, but not limited to, changes in QT/ QTc 
interval sfrom baseline) after enroll ment, the investigator will determine if the participant can 
continue in the study . The investigator, or qualified designee, is responsible for determining if 
any change in part icipant management is needed, and must document his/her review o f the ECG 
print ed at the time of co llection. 
Any new clinically relevant finding should be reported as an AE.
8.2.5. Clinical Laboratory Tests
See Appendix 2 (Secti on 10.2) for the list of clinical laboratory  tests to be performed and the 
SoA (Section 1.3) for the timing and frequency.
The invest igator must review the laboratory resul ts, docum ent this review, and report any 
clinically relevant changes occurring during the study  as an AE . 
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
30The laboratory  resul ts must be retained with source documents unless a Source Documen t 
Agreement or comparable document cites an electronic locat ion that accommodates the expected 
retenti on durati on. 
All laboratory  tests wi th values considered clinically  sign ificantly abnormal during participat ion 
in the study  shoul d be repeated until the values return to normal or baseline or are no longer 
considered clinically significant by  the investi gator or m edical mo nitor.
If such values do not return to normal/baseline within a peri od of  time judged reasonable 
by the investigator, the etio logy should be identified and the sponsor notified.
All protocol -requi red laboratory  assessments, as defined in Appendix 2 (Sect ion 10.2), 
must be conducted in accordance wit h the SoA (Section 1.3), standard collect ion 
requi rements , and l aboratory  manual .
If laboratory  values fro m non-protocol  specified l aboratory  assessments perform ed at an 
investigator -designated local laboratory require a change in part icipant management or are 
considered clinically significant by  the investi gator (e .g., SAE or AE or dose modification), then
report the information as an AE .
8.2.6. Pregnancy Testing 
Where applicable, pregnancy tests will be performed as outlined in the SoA ( Section 1.3).
8.2.7. Safety Monitoring
The Lilly CP or clinical research physician ( CRP )will mo nitor safety  data throughout the course 
of the study .
Lilly will review SAEs wit hin time frames mandated by co mpany procedures. The Lilly CP or 
CRP will periodically review the fo llowing data:
trends in safety  data
laboratory  analy tes
AEs.
When ap propri ate, the Lilly CP or CRP will consult with the funct ionally  independent Gl obal 
Patient Safet y therapeutic area physician or clinical research scient ist.
8.2.7.1. Hepatic Safety
Close hepatic monitoring
Laboratory  tests (Appendix 6, Secti on10.6), including ALT, AST, alkaline phosphatase ( ALP ) ,
and TBL, should be repeated, with the addit ion of direct bilirubin, gamma glutamyl  transf erase,
and creat ine kinase, wi thin 48 to 72 hours to confirm the abnormalit y and to determine if it is
increasing or decreasing, if 1 or more of these condit ions occur:
If a participant with baseline results of... develops the following elevations:
ALT or AST <1.5 ×ULN ALT or AST ≥3×ULN
ALP <1.5 ×ULN ALP ≥2×ULN

CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
31TBL <1.5 × ULNTBL ≥2×ULN (except for participants with Gilbert’s 
syndrome)
ALT or AST ≥1.5 ×ULN ALT or AST ≥2×baseline
ALP ≥1.5 ×ULN ALP ≥2×baseline
TBL ≥1.5 ×ULNTBL ≥1.5 ×baseline (except for participants with Gilbert’s 
syndrome)
If the abnormalit y persists or worsens, clinical and laboratory  monitoring and evaluat ion for
possible causes of abnormal liver tests should be init iated by  the invest igator in consultat ion with
the Lilly -designated CP. At a minimum, this evaluation should include physical examinat ion and
a thorough m edical history , including symptom s, recent illnesses (for example, heart failure,
systemic infect ion, hypotensio n, or seizures), recent travel, histo ry of concomi tant m edicati ons
(including over -the-counter), herbal and dietary  suppl ements, andhistory  of alcohol  drinking and
other substance abuse.
Initially, m onitoring of  symptoms and hepat ic biochemical tests should be done at a frequency o f
1 to 3 t imes weekly, based on the participant ’sclinical condit ion and hepat ic biochemical tests.
Subsequently, the frequency  of monitoring m ay be l owered to once every  1 to 2 weeks, if the
participant ’s clinical condit ion and l aboratory  results stabilize. Monitor ing of ALT, AST, ALP,
and TBL should continue unt il levels norm alize or return to approximate baseline levels.
Comprehensive hepatic evaluation
A co mprehensive evaluat ion shoul d be perform ed to search for possible causes of liver injury  if 
one or m ore of t hese condit ions occur:
If a participant with baseline results of... develops the following elevations:
ALT or AST <1.5 ×ULN ALT or AST ≥3×ULN with hepatic signs/symptoms*, or
ALT or AST ≥5×ULN
ALP <1.5 ×ULN ALP ≥3×ULN
TBL <1.5 × ULN TBL ≥2×ULN (except for participants with Gilbert’s syndrome)
ALT or AST ≥1.5 ×ULN ALT or AST ≥2×baseline with hepatic signs/symptoms*, or
ALT or AST ≥3×baseline
ALP ≥1.5 ×ULN ALP ≥2×baseline
TBL ≥1.5 ×ULN TBL ≥2 × baseline (except for participants with Gilbert’s syndrome) 
* Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, rash, and/or 
eosinophilia >5%.
At a minimum, this evaluat ion should include physical examinat ion and a thorough medical 
history , as outlined above, as well as tests for prothrombin t ime-internat ional normalized rat io; 
tests for viral hepatit is A, B, C, or E; tests for autoimmune hepat itis; and an abdo minal imaging 
study  (for example, ul trasound or com puted tom ography  scan).  
Based on the participant’s history  and ini tial resul ts, further testing should be considered in 
consultation wit h the Lilly -designated CP, including tests for hepat itis D virus, cytomegalo virus, 
Epstein -Barr virus, acetaminophen levels, acetaminophen protein adducts, urine toxicology  
screen, Wilson’s disease, blood alcoho l levels, urinary  ethyl glucuronide, and serum 
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
32phosphatidylethanol. Based on the circumstances an d the investi gator’s assessment of the 
participant’s clinical condit ion, the invest igator should consider referring the participant for a 
hepatol ogist or gastroenterologist consultation, magnet ic resonance cho langiopancreatography , 
endoscopi c retrograde ch olangi opancreatography , cardi ac echocardi ogram , or a liver biopsy.  
Additional hepatic data collection in study participants who have abnormal liver test 
results during the study
Addit ional hepatic safet y data collect ion in hepat ic safet y CRF shoul d be pe rformed in study  
participants who meet 1 or more of the fo llowing condi tions:  
Elevat ion of serum ALT to ≥5 × ULN on 2 or more consecutive blood tests (if baseline 
ALT <1.5× ULN)
oIn parti cipants wi th baseline ALT ≥1.5 × ULN, the thresho ld is ALT ≥3 × 
baseline on 2 or more consecutive tests
Elevated serum TBL to ≥2 × ULN (if baseline TBL <1.5 × ULN) (except for cases of 
known Gilbert’s syndro me)
oIn parti cipants wi th baseline TBL ≥1.5 × ULN, the thresho ld should be TBL ≥2 × 
baseline
Elevat ion of serum ALP to ≥2 × ULN on 2 or more consecutive blood tests (if baseline 
ALP <1.5 × ULN)
oIn parti cipants wi th baseline ALP ≥1.5 × ULN, the thresho ld is ALP ≥2 × baseline 
on 2 or more consecutive blood tests
Hepati c event consi dered to be an SAE
Discontinuati on of  study  interventi ondue to a hepati c event.
Note : The interval between the 2 consecut ive blood tests should be at least 2 day s.
8.3. Adverse Events ,Serious Adverse Events , and Product Complaints
The definit ions of the fo llowing events can be found in Appendix 3 (Secti on 10.3):
AEs
SAEs
Product complaints (PCs)
These events will be reported by  the parti cipant (or, when appropriate, by  a caregiver, surrogate, 
or the participant's legally authorized representative).
The invest igator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the sedefinit ionsand remain responsible for fo llowing up events that 
are seri ous, considered related to the study  intervent ion or study  procedures, or that caused the 
participant to di scont inue the study  intervent ionor study  (see Sect ion 7).
Care will be taken not to introduce bias when detecting events . Open -ended and non -leading 
verbal quest ioning of the participant is the preferred method to inquire about event occurrences.
Invest igators are responsible for monitoring the safety  of partici pants who have entered this 
study  and f or alerting Lilly  or its designee to any  event that seem s unusual, even if this event 
may be considered an unant icipated benefit to the participant.
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
33The invest igator is responsible for the appropriate medical care of participants during the study .
After the init ial report, the invest igator is required to proactively fo llow each participant at 
subsequent visits/contacts. All SAEs will be followed unt il reso lution, stabiliz ation, the event is 
otherwi se explained, or the participant is lost to follow- up (as defined in Sect ion 7.3). For PCs, 
the invest igator is responsi ble for ensuring that fo llow-up includes any supplemental 
investigat ions as indicated to elucidate the nature and/or causalit y.Further information on 
follow-up procedures is provided in Appendix 3 (Section 10.3).
8.3.1. Timing and Mechanism for Collecting Events
Thistable describes the timing, deadlines ,and m echanism for collect ing events.
Event Collection 
StartCollection 
StopTiming for Reporting 
to Sponsor or 
DesigneeMechanism for 
ReportingBack -up 
Method of 
Reporting
Adverse Event
AE Signing of 
the informed 
consent form 
(ICF)Participation 
in study has 
endedAs soon as possible 
upon site awarenessAE CRF N/A
Serious Adverse Event
SAE and SAE 
updates –prior 
to start of study 
interventio n and
deemed 
reasonably 
possibly related 
with study 
proceduresSigning of 
the ICFStart of 
interventio nWithin 24 hours of 
awarenessSAE paper form SAE paper 
form
SAE #and SAE 
updates –after 
start of study 
interventio nStart of 
interventio nParticipation 
in study has 
endedWithin 24 hours of 
awarenessSAE paper form SAE paper 
form
SAE* –after 
participant’s 
study 
participation has 
ended andthe 
investigator 
becomes awareAfter 
participant’s 
study 
participation 
has endedN/A Promptly SAE paper form N/A
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
34Event Collection 
StartCollection 
StopTiming for Reporting 
to Sponsor or 
DesigneeMechanism for 
ReportingBack -up 
Method of 
Reporting
Pregnancy
Pregnancy in 
female partners 
of male 
participantsAfter the 
start of study 
interventio n1 week after 
the last doseWithin 24 hours (see 
Section 8.3.2)Pregnancy paper 
formPregnancy 
paper form
Product Complaints
PCassociated 
with an SAE or 
might have led 
to an SAEStart of study 
interventio nEnd of study 
interventio nWithin 24 hours of 
awarenessPC form N/A
PC not 
associated with 
an SAEStart of study 
interventio nEnd of study 
interventio nWithin 1 business day 
of awarenessPCform N/A
Updated PC 
information— — As soon as possible 
upon site awarenessOriginally PCform 
with all changes 
signed and dated by 
the investigatorN/A
PC (if 
investigator 
becomes aware)Participation 
in study has 
endedN/A Promptly PCform
*SAEs shoul d not be reported unl ess the invest igator deems them to be possibly related to study 
treatm entor study  parti cipat ion.
8.3.2. Pregnancy
Collection of pregnancy information
Male participants w ith partners who become pregnant
The invest igator will attempt to collect pregnancy informat ion on any male participant’s 
female partner who becomes pregnant while the male participant is in this study . This 
applies only to male participants who receive study  intervent ion.
After learning of a pregnancy in the female partner of a study  parti cipant, the invest igator 
willobtain a consent to rel ease inform ationfrom the pregnant female partner directly, 
andwithin 24hours after obtaining this consent will record pregnancy informat ion on the 
appropriate form and submit it to the sponsor .
The female partner will also be fo llowed to determine the outcome of the pregnancy . 
Inform ation on the status of the mother and child will be forwarded to the sponsor. 
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
35Generally, the fo llow-up will be no l onger than 6 to 8 weeks fo llowing the estimated 
delivery  date. Any  terminat ion of the pregnancy will be reported regardless of gestati onal 
age, fetal status (presence or absence of ano malies), orindicat ion for the procedure.
8.4. Pharmacokinetics
Venous blood samples of approximately 2mL will be collected for measurement of plasma
concentrations of rosuvastatin and pirtobrutinib as specified in the SoA (Secti on 1.3).
A maximum of 3samples m ay be collected at additional t ime po ints during the study  if 
warranted and agreed upon between the invest igator and the sponsor. 
Instructi ons for the collect ion and handling of bio logical samples will be provided by the 
sponsor. The actual date and time (24-hour clock time) of each sample will be recorded.
8.4.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved by  the sponsor and stored at a facilit y 
designated by  the sponsor.
Concentrations o f rosuvastatin a nd pi rtobrutinib will be assayed using a validated liquid 
chromatography  tandem mass spectrom etry (LC-MS/MS )method.   
Bioanaly tical samples collected to m easure invest igational product concentrations will be 
retained for a maximum o f 1 year following l astparticipant visit for the study . During this time, 
sample sremaining after the bioanalyses may be used for exploratory  analyses such as 
metabo lism and/or protein binding work.
8.5. Pharmacodynamics
Pharmacodynamic parameters a re not evaluated in this study .
8.6. Genetics
A blood sam ple will be collected at screening to determine genetic polymorphisms for 
participants to m eet eligibilit y criteria prior to enrollment (Secti on 5.2and Section 5.2.1 ).
A separate blood sam ple will be collected for storage for potential pharmacogenet ic analysis as 
specified in t he SoA (Secti on1.3).See Appendix 5 (Section 10.5)for informat ion regarding 
genet ic research. 
8.7. Biomarkers
Biomarkers are not eval uated in thi s study .
8.8. Immunogenicity Assessments
Immunogenicit y is not evaluated in this study . 
8.9. Health Economic s
This sect ion is not applicable for this study.
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
369. Statistical Considerations
The stati stical analysis plan (SAP) will be finalized prior to first participant first visit, and it will 
include a more technical and detailed descript ion of the statist ical analyses described in this 
section. This sect ion is a summary o f the planned stati stical analyses.
9.1. Statistical Hypotheses
The primary  object ive variables will be evaluated to assess the potential DDI. No significant 
DDI for rosuvastatin will be concluded if the respective 90% confidence interval for area under 
the concentration versus time curve from t ime zero to infinit y (AUC[0 -∞]) and maximum 
observed drug concentration ( Cmax) is completely contained wit hin the no -effect boundaries 
(0.80, 1. 25).
9.2. Analyses Sets
The fo llowing popul ations are defined:
Population Description
Entered All participants who sign the ICF. 
Enrolled All participants assigned to study  intervent ion, regardless of 
whether they  take any dos es.
Safety All participants who receive at least 1 dose of rosuvastati n.
Parti cipants will be analyzed according to the intervent ion they 
actually received .
Pharmacokinet ic All participants who receive at least 1 do se of rosuvastatin and
have evaluable PK data.
9.2.1. Study Participant Disposition
All participants who discont inue from the study  will be ident ified and the extent of their
participat ion in the study will be reported. If known, a reason for their discont inuat ion will be
given. 
A detailed description o f participant disposi tion will be provided at the end of the study .
9.2.2. Study Participant Characteristics 
The parti cipant’s age, sex, weight, height, andother demographic characterist ics will be 
recorded.
9.3. Statistical Analyses
Statistical analysis o f this study  will be the responsibilit y of the sponsor or its designee.
Any change to the data analysis methods described in the protocol will require an amendm ent 
only if it changes a princi pal feature of the protocol. Any  other change to the data analysis 
methods described in the protocol, and the just ification for making the change, will be described 
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
37in the SAP and the clinical study  report. Addi tional exploratory analyses of the data will be 
conducted as deemed appropriate.
Study  resul ts may be pooled wi th the resul ts of other studi es for safet y and popul ation PK 
analysis purposes to avoid issues wit h post -hoc analyses and inco mplete di sclosures of analyses.
9.3.1. P harmacokinetic Analyses
All PK analyses will be made using the Pharmacokinet ic Populat ion.
9.3.1.1. Pharmacokinetic Parameter Estimation
PKparameter estimates for rosuvastatin will be calculated by standard nonco mpart mental 
methods of analysis.
The primary  paramet ers for analysis will be C maxand AUC (0-∞) of rosuvastatin . Other 
nonco mpart mental param eters, such as tmax, t1/2, apparent clearance, and apparent volume of 
distribut ion may be reported.
Blood sam ples collected for the PK of pirtobrutinib alo ne will be used to determine plasma 
concentration only, to ensure sufficient exposure. 
9.3.1.2. Pharmacokinetic Statistical Inference
PKparameters will be evaluated to estimate drug interaction for rosuvastatin with 
single (Day  6) 
and mult iple (D ay 13) doses of pirtobrutinib . A subject m ay be excluded from  the PK summary  
statist ics and statist ical analysis if the subject has an AE of vo miting that occurs at or before 
2times m edian tmax.
Log-transform ed C maxand AUC(0 -∞) param eters for rosuvastatin will be evaluated ina linear
mixed -effects m odel with a fixed effect for treatm ent,and a random effect for participant. The 
treatm ent differences will be back transformed to present the ratios of geometric means and the 
corresponding 90% confidence interval.
The t maxwill be analyzed using a Wilcoxon signed rank test. Estimates of the median difference 
based on the observed medians, 90% confidence intervals ,and p -values fro m the Wilcoxon test 
will be calculated.
9.3.2. Safety Analy ses 
All safet y analyses will be made using the Safet y Popul ation.
9.3.2.1. Clinical Evaluation of Safety
All invest igational product and protocol procedure AEs will be listed, and if the frequency o f 
events allows, safet y data will be summarized using descript ive methodol ogy.
The incidence of AEs for each treatment will be presented by  severi ty and by associ ation with 
investigat ional product as perceived by  the investigator. AEs reported to occur prior to 
enrollment will be dist inguished from those reported as new or increased in severit y during the 
study . Each AE will  be classified by the most suitable term fro m the medical regulatory  
dictionary.AEs by day o f onset will be presented. 
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
38The number of SAEs will be reported.
9.3.2.2. Statistical Evaluation of Safety
Safety parameters that will be assessed include safety  laboratory  parameters andvital signs. The 
param eters will  be listed, and summarized using standard descript ive statist ics. Addit ional 
analysis will be performed if warranted upon review of the data .
9.4. Interim Ana lysis 
No interim analyses are planned for this study . If an unplanned interim analysis is deemed 
necessary  for reasons other than a safet y concern, the protocol must be amended.
9.5. Sample Size Determination
CCI
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
3910. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regulatory and Ethical Considerations
This s tudy will be conducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizat ions of Medical Sciences 
International Ethical Guidelines
Applicable ICH Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations .
The protocol, protocol amendments, ICF, Investigator ’sBrochure (IB), and other relevant 
docum ents ( for example , advert isements) must b e submitted to an institutional review board 
(IRB)/ independent ethics co mmit tee (IEC)by the investigator and reviewed and approved by the 
IRB/IEC before the study is init iated.
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study  design, except for changes necessary  to eliminate an immediate 
hazard to study  parti cipants.
Protocol s and any substantial amendments to the protocol will require healt h authorit y approval  
prior to init iation exc ept for changes necessary  to eliminate an immediate hazard to study  
participants .
The invest igator will be responsible for the fo llowing:
Provi ding wri tten summaries of the status of the study  to the IRB/IEC annually  or m ore 
frequently in accordance with t he requirements, policies, and procedures established by 
the IRB/IEC
Notifying the IRB/IEC of SAEs or other si gnificant safet y findings as required by 
IRB/IEC procedures
Provi ding oversight of study  conduct for parti cipants under thei r responsibilit y and 
adherence to requirements of 21 C ode of Federal Regulations (C FR), ICH gui delines, the 
IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulat ions.
Invest igator sites are compensated for participat ion in the study as detailed in the clinical trial
agreem ent.
10.1.2. Informed Consent Process
The investigator or the invest igator’s representative will explain the nature of the study , 
including the risks and benefit s,to the participant and answer all questi ons regarding the study .
Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary. Partici pants will be requi red to 
sign a statem ent of  inform ed consent that meets the requirements of 21 CFR 50, local 
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
40regul ations, ICH guidelines, privacy and data pr otecti on requi rements, where applicable, and the 
IRB/IEC or study  center.
The m edical  record m ust include a statem ent that wri tten inform ed consent was obtained before 
the participant was enter ed in the study  and the date the written consent was obtained. The 
authori zed person obtaining the informed consent must also sign the ICF.
Parti cipants m ust be reconsented to the most current version of the ICF(s) during th eir 
participat ion in the study.
A copy  of the ICF(s) m ust be provi ded to the participant and is kept on file .
Parti cipants who are rescreened are required to sign a new ICF.
10.1.3. Data Protection
Parti cipants will be assigned a unique ident ifier by the sponsor. Any part icipant records ,datasets
or tissue samples that are transferred to the sponsor will contain the identifier only; participant 
names or any  information which would make the participant ident ifiable will not be transferred.
The parti cipant must be informed that the participant’s personal study -related data will be used 
by the sponsor in accordance wit h local data protecti on law. The l evel of disclo sure m ust al so be 
explained to the participant who will be required to give consent for theirdata to be used as 
described in the informed consent .
The par ticipant must be informed that theirmedical records m ay be examined by Clinical 
Qualit y Assurance auditors or other authorized personnel appo inted by  the sponsor, by  
appropriate IRB/IEC members, and by inspectors from regulatory  authori ties.
The sponsor h as processes in place to ensure data protection, informat ion securit y and data 
integrity. These processes include appropriate contingency plan(s) for appropriate and timely 
response in the event of a data securit y breach.
10.1.4. Dissemination of Clinical Study Da ta
Communication of Suspended or Terminated Dosing
If a decisio n is taken to suspend or terminate dosing in the study due to safet y findings, this 
decisio n will be communicated by Lilly to all investigators (for example, by phone and/or email) 
as soon as possible. It will be a requirement that investigators respond upon receipt to confirm 
that they  understand the communi cation and have taken the appropriate action prior to further 
dosing any participants with study  intervent ion. Any invest igator not responding will be 
followed up by  Lilly personnel pri or to any  further planned dosing. If a dose is planned 
imminent ly, Lill y personnel  will immediately, and continually, use all efforts to reach 
investigators until contact is made and instructions verified.
Reports
The sponsor will disclose a summary o f study  information, including tabular study results, on 
publicly  available websites where required by  local law or regul ation. 
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
41Data 
The sponsor does not proactively  share data from  Phase 1 clinical studies . Requests for access to 
Phase 1 clinical study data are evaluated on a case -by-case basis taking into considerat ion the 
abilit y to anonymize the data and the nature of the data collected.
10.1.5. Data Quality Assurance
All participant data relat ing to the study  will be recorded on printed or electronic CRFs unless 
transmitted to the sponsor or designee electronically ( for example , laboratory  data). The 
investigator is responsible for verifying that data entries are accurate and correct by  physically  or 
electroni cally signing the CRF.
The invest igator must maintain accurate documentation (source data) that supports the 
inform ation entered in the CRF. Source data may include laboratory  tests, m edical records, and 
clinical notes.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, and regulatory  
agency  inspect ions and provide direct a ccess to source data docum ents.
Moni toring details describing strategy  (for example , risk-based init iatives in operations and 
qualit y such as risk m anagement and mit igation strategi es and analy tical risk -based mo nitoring), 
methods, responsibilit ies and requirements, including handl ing o f nonco mpliance issues and 
monitoring techniques ,are provi ded in the Moni toring Pl an.
The sponsor or designee is responsible for the data management of this study ,includin g quali ty 
checking o f the data.
The sponsor assumes accountabilit y for acti ons delegated to other individuals (e.g. , contract 
research organizat ions).
Study  monitors will perform  ongoing source data verification to confirm that data entered into 
the CRF by  authori zed si te personnel  are accurate, com plete, and verifiable fro m source 
docum ents; that the safet y and ri ghts of  parti cipants are being protected; and that the study  is 
being conducted in accordance with the current ly approved protocol and any other study 
agreem ents, ICH GCP, and all applicable regu latory requirements.
Records and documents, including signed ICFs, pertaining to the conduct of this study must be 
retained by the invest igator for the time period outlined in the Clinical Trial Agreement (CTA)
unless local regulat ions or inst itutional policies requi re a l onger reten tion peri od. No records m ay 
be destroy ed during the retention period without the written approval of the sponsor. No records 
may be transferred to another location or party  without wri tten notificat ion to the sponsor .
In addit ion, the sponsor or its representatives will periodically  check a sample of the participant
data recorded against source documents at the study site. The study  may be audi ted by  the 
sponsor or its representatives, and/or regulatory  agencies at any  time. Invest igators will be given 
notice before an audit occurs.
Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor.
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
42An electronic data capture sy stem  will be used in this st udy for the collect ion of CRF data. The 
investigator maintains a separate source for the data entered by  the invest igator or designee into 
the sponsor -provided electroni c data capture system . The investi gator is responsible for the 
ident ificat ion of any da ta to be considered source and for the confirmat ion that data reported are 
accurate and complete by  signing the CRF .
10.1.6. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collecte d. Source documents are filed at the invest igator’s site.
Data reported onor entered in the CRF and are transcribed fro m source docum ents m ust be 
consistent with the source documents or the discrepancies must be explained. The invest igator 
may need to request previous medical records or transfer records, depending on the study . Also, 
current m edical records must be available.
Definit ion of what constitutes source data can be found in Section 10.1.5 .
10.1.7. Study and Site Start and Closure
First Act of Rec ruitment
The study  start date is the date on which the clinical study  will be open for recruit ment of 
participants.
Study or Site Termination
The sponsor designee reserves the right to close the study  site or terminate the study  at any  time 
for any  reason at the sol e discret ion of the sponsor. Study  sites will  be cl osed upon study  
completion. A study  site is considered cl osed when all required documents and study  supplies 
have been co llected and a study -site closure visi t has been perform ed.
The invest igator may init iate study -site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by the sponsor or investigator may  include but are 
not limited to:
For study  terminat ion:
Discontinuati on of  further study  intervent ion developm ent.
For si te terminati on:
Failure of the invest igator to comply wi th the protocol , the requi rements of the IRB/IEC 
or local health authori ties, the sponsor's procedures, or GCP guidelines
Inadequate recruit ment (evaluated after a reasonable amount of time) of parti cipants by 
the invest igator
Total  number of participants included earlier than expected .
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
investi gators, the IECs/IRBs, the regulatory  authorit ies, and any contract research organizat ion(s) 
used in the study  of the reason f or terminat ion or suspensio n, as specified by the applicable 
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
43regul atory  requi rements. The investigator shall prompt ly inform  the participant and shoul d assure 
appropriate participant therapy  and/or foll ow-up.
10.1.8. Publication Policy
In accordance with the sponsor’s publication po licy, the results of this study  will be submitted 
for publicat ion by a peer -reviewed journal if the results are deemed to be of significant medical 
importance.
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
4410.2. Appendix 2: Clinical Laboratory Tests
The tests detailed in the table below will be performed by the local laboratory .
Protocol -specific requirements for inclusio n or exclusio n of participants are detailed in Sect ion 5
of the protocol.
Addit ional tests may be performed at any  time during the study  as determined necessary  by the 
investigator or required by  local regulati ons.
Invest igators must document their review of thelaboratory  safety resul ts.
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
45Clinical Laboratory Tests
Hematology Clinical Chemistry
Hematocrit Alanine aminotransferase
Hemoglobin Albumin
Erythrocy te count (RBC) Alkaline phosphatase
Mean cell volume Aspartate aminotransferase
Mean cell hemoglobin Bicarbonate
Mean cell hemoglobin concentration Blood urea nitrogen
Leukocytes (WBC) Calcium
Platelets Chloride
Differential WBC (Absolute counts and %) of: Cholesterol
Basophils Creatinine
Eosinophils Creatinine phosphokinase
Lymphocy tes Gamma -glutamyl transferase
Monocytes Glucose (random)
Neutrophils Potassium
Sodium
Total bilirubin a
Urinaly sis Total protein
Bilirubin Uric acid
Blood 
Glucose Serology b
Ketones Hepatitis B surface antigen
Nitrite Hepatitis C antibody
pH Human immunodeficiency virus
Protein
Specific gravity Ethanol testing d
Urobilinogen Urine drug screen (including cotinine) e
Microscopic examination of sediment c Follicle -stimulating hormone b,f
Pregnancy test g
Abbreviations: RBC = red blood cells; WBC = white blood cells.
Note: Results of these assays will be validated by the local laboratory at the time of testing. Additional tests may be 
performed or auto -calculated by the laboratory as part of its standard panel that cannot be removed. Some of the 
abov e parameters are calculated from measured values. Omission of calculated values will not be considered as a 
protocol violation.
aDirect and indirect bilirubin will be analyzed if total bilirubin is elevated.
bPerformed at screening only .
cTest only if dipstick result is abnormal .
dPerformed at check -in (Day -1) only .
ePerformed at screening and check-in (Day -1) only .
fFemales only to confirm postmenopausal status.
gPerformed in serum at screening and in urine at all other times. A positive urine pregnancy test will be confirmed 
with a serum pregnancy test. 
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
4610.2.1. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all
blood sam pling during the study . 
Protocol J2N -MC -JZNW Sampling Summary
PurposeBlood Volume per 
Sample (mL)Number of Blood 
SamplesTotal Volume 
(mL)
Screening tests a 21.5 1 21.5
Clinical laboratory tests a 12.5 8 100
Rosuvastatin pharmacokinetics b 2 53 106
Pirtobrutinib pharmacokinetics b 2 15 30
Pharmacogenetics for storage 10 1 10
Total 267.5
Total for clinical purposes 270
aAdditional samples may be drawn if needed for safety purposes.
bIncludes additional 3 samples, if required.
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
4710.3. Appendix 3: Adverse Events and Serious Adverse Events : Definitions 
and Procedures for Recording, Evaluating, Follow- up, and 
Reporting
10.3.1. Definition of Adverse Event
AE Definition
An AE is any  untoward m edical occurrence in a participant administered a 
pharmaceutical product and which does not necessarily have a causal relat ionship with 
the study  intervent ion. An AE can therefore be any unfavourable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease (new or exacerbated)
temporally associated with the use of a medicinal (investigat ional) product, whether or 
not rel ated to the m edicinal (investigational) product.
Events Meeting the AE Definition
Any abnormal laboratory  test resul ts (hematol ogy, clinical chemistry , or uri nalysis) or 
other safet y assessments ( for example , ECG, radi ological scans, vi tal signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the invest igator ( that is, not rel ated 
to progression of underlying disease).
Exacerbat ion of a chronic or intermittent pre -exist ing condit ion including either an 
increase in frequency and/or intensit y of the condi tion.
New condit ion detected or diagnosed after study  intervent ion administration even 
though it
may have been present before the start of the study .
Signs, symptoms, or the clinical sequelae of a suspected DDI.
Signs, symptoms, or the clinical sequelae of a sus pected overdose of either study  
intervent ion or a concomitant medicat ion. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdose sshoul d be reported regardless of sequelae.
Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments thatare associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condit ion.
The disease/disorder being studied or expected progressio n, signs, or symptom s of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condi tion.
Medical or surgical procedure ( for example , endoscopy , appendectomy ): the condi tion 
that leads to the procedure is the AE.
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
48Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admissio n to a hospital).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condit ion(s) present or 
detected at the start of the study  that do not worsen.
10.3.2. Definition of S erious Adverse Event
An SAE is defined as any untoward medical occurrence that, at any dose , meets one or 
more of the criteria listed :
a.Results in death
b.Is life -threatening
The term  life-threatening in the definit ion of serious refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused de ath, if it were m ore severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalizat ion signifies that the participant has been admi tted to hospi tal or 
emergency ward (usually invo lving at least an overnight stay) for observat ion and/or 
treatm ent that woul d not have been appropriate in the physician’s office or outpatient 
setting. Co mplications that occur during hospitalization are AEs. If a co mplication 
prolongs hospitalizat ion or fulfills any other serious criteria, the event i s seri ous. When 
in doubt as to whether hospitalizat ion occurred or was necessary , the AE shoul d be 
considered serious.
Hospitalization for elect ive treatment of a pre -existing condit ion that di d not worsen 
from baseline is not consider ed an AE.
d.Results in persistent disability/incapacity
The term disabili ty means a substant ial disrupt ion of a person’s abilit y to conduct 
norm al life f unctions.
This definit ion is not intended to include experiences of relat ively minor medical 
significance such as unco mplicated headache, nausea, vomit ing, di arrhea, influenza, 
and accidental trauma ( for example , sprained ankle) which may  interfere wi th or 
prevent every day life f unctions but do not constitute a substant ial disruption.
e.Is a congenital anomaly/birth defect
Abnorm al pregnancy outcom es (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital ano malies, ectopi c pregnancy) are considered SAEs.
f.Other situations:
Medical or scient ific judgment should be exercised by the inv estigator in deciding 
whether SAE reporting is appropriate in other situations such as important medical 
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
49events that may  not be immediately life- threatening or resul t in death or hospitalizat ion 
but m ay jeopardi ze the parti cipant or m ay require medical or surgical intervent ion to 
prevent one of the other outcomes listed in the above definit ion. These events should 
usually be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergi c bronchospasm , blood dyscrasias or 
convulsio ns that do not result in hospitalizat ion, or development of drug dependency or 
drug abuse.
10.3.3. Definition of Product Complaints
PCs
A PCis any written, electronic, or oral co mmunication that alleges deficiencies related 
to the i dentity, qualit y, durabilit y, reliabilit y, safety , effectiveness or perform ance of a 
study interventi on.When the abilit y to use the study  intervent ion safely  is impacted, 
the following are also PCs:
oDeficiencies in labeling informat ion, and
oUse errors for device or drug-device combination products due to ergonomic 
design elements of the product.
PCsrelated to study  interventi ons used in clinical studi esare collec ted in order to 
ensure the safet y of parti cipants, m onitor quali ty, and to facili tate process and product 
improvements.
Invest igators will instruct p articipants to contact the siteas soon as possible if he or she 
has a PCor probl em wi th the study  interventionso that the si tuation can be assessed.
An event may meet the definit ion of both a PCand an AE/SAE. In such cases, it 
shoul d be reported as both a PCand as an AE/SAE.
10.3.4. Recording and Follow -Up of AE and/or SAE and Product Complaints
AE,SAE ,and PCRecording
When an AE/SAE /PC occurs, i t is the responsibility  of the invest igator to review all 
docum entati on (for example , hospi tal progress notes, l aboratory  reports, and 
diagnosti cs reports) rel ated to the event.
The invest igator will then record all re levant AE/ SAE /PCinformat ion in the 
participant’s m edical  records, in accordance wit h the invest igator’s normal clinical 
practi ce. AE/SAE inform ation is reported o n the appropriate CRF page and PC
inform ation is reported on the PCForm .
Note: An event may meet the definit ion of both a PCand an AE/SAE. In such cases, it 
shoul d be reported as both a PCand as an AE/SAE.
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
50It is notacceptable for the invest igator to send photocopies of the participant’s medical 
records to the sponsor or designee in lieu of completion of the CRF page for AE/SAE 
and the PCForm  for product complaints .
There m ay be instances when copies of medical records for certain cases are requested 
by the sponsor or desi gnee . In this case, all participant identifiers, with the except ion of 
the participant number, will be redacted on the copies of the medical records before 
submissio n to the sponsor or designee .
The invest igator will attempt to establish a diagnosis of the eve nt based on signs, 
symptoms, and/or other clinical informat ion. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE .
Assessment of Intensity
The invest igator will make an assessment of intensit y for each AE and SAE reported during 
the study  and assign it to oneof the fo llowing categori es:
Mild: A type of AEthat is usually  transient and may  requi re only  minimal  treatm ent or 
therapeuti c interv ention. The event does not generally  interfere wi th usual act ivities of 
daily  living .
Moderate: A type of AEthat is usually alleviated with addit ional specific therapeut ic 
intervent ion. The event interferes wit h usual activit ies of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research 
participant .
Severe: A type of AEthat interrupts usual act ivities of daily living, or significant ly 
affects clinical status, or may require intensive therapeutic intervention . An AE that i s 
assessed as severe should not be confused with a nSAE. Severe is a category  utilized 
for rati ng the intensit y of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least oneof the predefined outcomes 
as described in the definit ion of an SAE, NOT when it is rated as severe.
Assessment of Causality
The invest igator is obligated to assess the relationship between study intervent ion and 
each occurrence of each AE/SAE. The investigator will use clinical judgment to 
determine the relat ionship .
A “reasonable possibilit y”of a rel ationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relat ionship, rather than a relat ionship cannot be 
ruled out.
Alternat ive causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study  intervent ion 
administration will be considered and invest igated.
The invest igator will also consu lt the IB and/or Product Information, for marketed 
products in theirassessment.
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
51For each AE/SAE, the invest igator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
There m ay be si tuations i n which an SAE has occurred and the invest igator has 
minimal informat ion to include in the init ial report to the sponsor or desi gnee . 
However, it is very  important that the invest igator always make an assessment of 
causalit y for every  event before the init ial transmission of the SAE data to the sponsor
or desi gnee .
The invest igator may change theiropinio n of causalit y in light of fo llow-up 
inform ation and send a SAE follow -up report wi th the updated causalit y assessment.
The causalit y assessment i s one of the criteria used when determining regulatory  
reporting requirements.
Follow -Up of AEs and SAEs
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by the sponsor 
or desi gnee to elucidate the nature and/or causalit y of the AE /SAE as fully as possibl e. 
This m ay include addit ional laboratory  tests or investigations, histopathological 
examinat ions, or consultation with other health care professio nals.
If a participant dies during participation in the study or during a recognized fo llow-up 
period,the investigator will provide the sponsor or desi gnee with a copy  of any 
post-mortem findi ngs including histopathology . 
10.3.5. Reporting of S erious Adverse Events
SAE Reporting via SAE Report
Facsimile transmissio n of the SAE Report is the preferred method to transmit this 
inform ation to the sponsor or designee.
Initial notificati on via telephone does not replace the need for the invest igator to 
complete and sign the SAE Report within the designated reporting time frames.
Contacts for SAE reporting can be found in the SAE Report.
10.3.6. Regulatory Reporting Requirements
SAE Regulatory Reporting
Prom ptnotificat ion by the invest igator to the sponsor of a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the safet y of parti cipants and the safet y 
of a study  intervent ion under clinical invest igation are met.
The sponsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and 
other regulatory  agencies about the safet y of a study  intervent ion under clinical 
investigat ion. The sponsor will co mply with country -specific regulatory  requi rements 
relating to safet yreporting to the regulatory  authorit y, IRB/IEC, and invest igators.
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
52An invest igator who receives an invest igator safety report describing a SAE or other 
specific safet y informat ion (e.g., summary or list ing of SAEs) fro m the sponsor will 
review and then fi le it along wi th the IB and will notify the IRB/IEC, if appropriate 
according to local requirements.
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
5310.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Definitions
Females of Childbearing Potential
Females are considered a woman of childbearing potential if
they have had at l east 1cycle of menses, or
they have Tanner 4 breast development .
Any amount of spotting should be considered menarche. 
Females NOT of Childbearing Potential
Females are considered wo men not of childbearing potential if
they have a congenital ano maly such as Mullerian agenesis 
they are infertile due to surgical sterilizat ion
ohysterectomy
obilateral  oophorectomy
otubal  ligation
they are post -menopausal.
Post-Menopausal
The post -menopausal state should be defined as:
1.A female at any  age at l east 6 weeks post -surgical bilateral oophorectomy with or without 
hysterectomy, confirmed by operative note; or 
2.A female at l east 40 y ears of age and up to 55 y ears ol d with an intact uterus, not on 
horm one therapy *, who has had ce ssation of menses for at least 12 consecut ive months 
without an al ternat ive medical cause ;AND 
With a fo llicle -stimulating horm one >40 m IU/mL; or 
3.A female 55 or ol der not on hormone therapy , who has had at l east 12 m onths of 
spontaneous amenorrhea, or
4.A female at l east 55 y ears of age wi th a diagnosis of m enopause pri or to starting horm one 
replacement therapy
* Female participants should not be taking medicatio ns during amenorrhea such as oral 
contraceptives, hormones, gonadotropin -releasing horm one, ant i-estrogens, select ive estrogen 
receptor modulators (SERMs), or chemotherapy  that coul d induce transient amenorrhea.
10.4.2. Contraception Guidance
10.4.2.1. Female Participants
Females of childbearing potential are excluded from this study . 
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
54Female participants not of child bearing potential, as defined in Sect ion10.4.1 , may participate in 
this study and are not required to adhere to contraceptive requirements. 
All female participants must test negative for pregnancy prior to init iation o f treatm ent as 
indicated by  a negat ive serum pregnancy  test at the screening visit followed by a negat ive urine
pregnancy test within 24 hours prior to exposure (Day  -1). A posi tive urine test will be 
confirmed wit h a serum pregnancy test.
10.4.2.2. Male Participants
Male parti cipants, regardless of their fertilit y status, with partners who are non -pregnant females 
of childbearing potential, must agree to either
1.remain abst inent (if this is their pref erred and usual lifest yle), or
2.use condoms with spermicide plus 1 addit ional highly  effect ive contraception method 
(see Section 10.4.3 ), during intercourse.
They  must agree to adhere to these restrict ions for the durati on of  the study  and for 6 months
after the l ast dose of study  intervent ion.
Male parti cipants wi th pregnant partners must agree to use condoms with spermicide during 
intercourse.
All male part icipants should refrain from sperm donat ion for the durati on of  the study  and f or 
6monthsafter the l ast dose of study  interventi on.
10.4.3. Contraception Methods
This table illustrates examples of highly effect ive, effect ive, and ineffect ive forms of 
contraception. 
Methods Examples
Highly effective contraceptioncombination oral contraceptive pill and 
mini-pill
implanted contraceptives
injectable contraceptives
contraceptive patch (only women 
<198 pounds or 90 kg)
total abstinence
vasectomy (if only sexual partner)
fallopian tube implants (if confirmed by 
hysterosalpingogram )
combined contraceptive vaginal ring, or 
intrauterine devices
Effective contraception male or female condoms with spermicide 
diaphragms with spermicide or cervical 
sponges
barrier method with use of a spermicide
ocondom with spermicide
odiaphragm with spermicide, or
ofemale condom with spermicide
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
55Note:  The barrier method must include use of a 
spermicide (i.e., condom with spermicide, 
diaphragm with spermicide, female condom with 
spermicide) to be considered effective.
Male and female condoms should not be used in 
combination.
Ineffective forms of contraceptionspermicide alone 
immunocontrac eptives
periodic abstinence
fertility awareness (calendar method, 
temperature method, combination of 
above 2, cervical mucus, symptothermal)
withdrawal
post coital douche
lactational amenorrhea
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
5610.5. Appendix 5: Genetics
CCI
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
5710.6. Appendix 6: Liver Safety: Suggested Actions and Follow -up 
Assessments 
See Secti on8.2.7.1 for guidance on appropri ate test sel ection.
The Lilly -designated central laboratory  must com plete the analysis of all selected testing except
for microbi ology testing.
Local  testing m ay be performed in addit ion to central testing when necessary for immediate
participant m anagement.
Results will be reported if a validated test or calculation is available.
Hematology Clinical Chemistry
Hemoglobin Total bilirubin (TBL)
Hematocrit Direct bilirubin
Erythrocy tes (RBCs -red blood cells) Alkaline phosphatase (ALP)
Leukocytes (WBCs -white blood cells) Alanine aminotransferase (ALT)
Differential: Aspartate aminotransferase (AST)
    Neutrophils, segmented Gamma -glutamyl transferase (GGT)
    Lymphocytes Creatine kinase (CK)
    Monocytes Other Chemistry
    Basophils Acetaminophen
    Eosinophils Acetaminophen protein adducts
Platelets Alkaline phosphatase isoenzymes
Cell morphology (RBC and WBC) Ceruloplasmin
Copper
Coagulation Ethyl alcohol (EtOH)
Prothrombin time, international normalized ratio (INR) 
(PT-INR)Haptoglobin
SerologyImmunoglobulin IgA (quantitative)
Hepatitis A virus (HAV) testing: Immunoglobulin IgG (quantitative)
    HAV total antibody Immunoglobulin IgM (quantitative)
    HAV IgM antibody Phosphatidylethanol (PEth)
Hepatis B virus (HBV) testing: Urine Chemistry
    Hepatitis B surface antigen (HBsAg) Drug screen
    Hepatitis B surface antibody (anti -HBs) Ethyl glucuronide (EtG)
    Hepatitis B core total antibody (anti -HBc) Other Serology
    Hepatitis B core IgM antibody Anti- nuclear antibody (ANA)
    Hepatitis B core IgG antibody Anti-smooth muscle antibody (ASMA) a
    HBV DNA d Anti- actin antibody b
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
58Hepatitis C virus (HCV) testing: Epstein -Barr virus (EBV) testing:
    HCV antibody     EBV antibody
    HCV RNA d     EBV DNA d
Hepatitis D virus (HDV) testing: Cytomegalovirus (CMV) testing:
    HDV antibody     CMV antibody
Hepatitis E virus (HEV) testing:     CMV DNA d
    HEV IgG antibody Herpes simplex virus (HSV) testing:
    HEV IgM antibody     HSV (Type 1 and 2) antibody 
    HEV RNAd     HSV (Type 1 and 2) DNA d
Microbiology c Liver kidney microsomal type 1 (LKM -1) antibody
Culture:
    Blood
    Urine
aNot required if anti -actin antibody is tested.
bNot required if anti -smooth muscle antibody (ASMA) is tested.
cAssay ed ONLY by investigator -designated local laboratory; no central testing available.
dReflex/confirmation dependent on regulatory requirements, testing availability, or both.
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
5910.7. Appendix 7: Abbreviations
Term Definition
AE adverse event
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC(0 -∞) area under the concentration versus time curve from time zero to infinity
BCRP breast cancer resistance protein
BTK Bruton’s tyrosine kinase
CFR Code of Federal Regulations
Cmax maximum observe d drug concentration
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies related to 
the identity, quality, purity, durability, reliability, safety or effectiveness, or performance of a 
drug o r drug delivery system.
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
CP clinical pharmacologist
CRF case report form; a printed, optical, or electronic document designed to record all of the protocol -
required information to be reported to the sponsor for each study participant .
CRP clinical research physician: Individual responsible for the medical conduct of the study. 
Responsibilities of the CRP may be performed by a physician, clinical research scientist, global 
safety physician or other medical officer.
CRU clinical research unit
CV coefficient of variation
DDI drug-dr ug interaction
ECG electrocardiogram
enroll The act of assigning a participant to a treatment. Participants who are enrolled in the study are 
those who have been assigned to a treatment.
enter Participants entered into a study are those who sign the ICFdirectly or through their legally 
acceptable representatives.
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
60GCP good clinical practice
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
IEC independent ethics committee
informed 
consentA process by which a participant voluntarily confirms their willingness to participate in a 
particular study, after having been informed of all aspects of the study that are relevant to the 
participant’s decision to participate. Informed consent is documen ted by  means of a written, 
signed and dated ICF.
investigation
al productA pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a 
clinical study , including products already on the market when used or assembled (for mulated or 
packaged) in a way different from the authorized form, or marketed products used for an 
unautho rized indication, or marketed products used to gain further information about the 
autho rized form.
IRB institutional review board
participant Equiva lent to CDISC term “subject”: an individual who participates in a clinical study, either as 
recipient of an investigational medicinal product or as a control
PC product complaint
PK pharmacokinetic (s)
QD once daily
QTc corrected QT interval
SAE serious adverse event
SAP statistical analysis plan
screen The act of determining if an individual meets minimum requirements to become part of a pool of 
potential candidates for participation in a clinical study. 
SoA Schedule of Activities
t1/2 terminal half -life
TBL total bilirubin
TEAE Treatment -emergent adverse event:  An untoward medical occurrence that emerges during a 
defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state, and does not nec essarily have to have a causal relationship with this treatment.
tmax time to maximum drug concentration
ULN upper limit of normal
CONFIDENTIAL Protocol  number J2N-MC-JZNW (a)
6111. References
Crestor ®(rosuvastatin calcium) Tablets [Prescribing Information]. Wilmington, DE: 
AstraZeneca Pharmaceut icals LP; 2003. Revised May 2020. Accessed at 
https://www.azpicentral.co m/crestor/crestor.pdf#page=1 on 15 September 2021. 
Food and Drug Administration (FDA). Drug Development and Drug Interactions. Table of 
Substrates, Inhibitors and Inducers. Accessed at https://www.fda.gov/drugs/drug- interacti ons-
labeling/drug -devel opment -and-drug-interacti ons-table -substrates -inhibitors -and-inducers on 
19August 2021.
Furukawa T, Wakabayashi K, Tamura A, et al.Major SNP (Q141K) variant of human ABC 
transport er ABCG2 undergoes lysoso mal and proteaso mal degradat ions. Pharm Res . 
2009;26(2):469 -479.
International Transporter Consortium ;Giaco mini KM, Huang SM, Tweedie DJ, et al. Membrane 
transporters in drug development. Nat Rev Drug Discov . 2010;9(3):215 -
236.
Keskitalo JE, Zolk O, Fromm  MF, et al. ABCG2 polymorphism markedly affects the 
pharmacokinet ics of atorvastatin and rosuvastatin. Clin Pharmacol Ther . 2009;86(2):197 -
203.
Mendes P, Robles GP, Mathur S. Statin
-induced rhabdo myolysis: a comprehensive review of 
case reports. Physiother Can. 2014;66(2):124 -132.
Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genet ically 
polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 
2011;63(1):157 -
181.
Wan Z, Wang G, Li T, et al.Marked alteration of  
rosuvastatin pharm acokinetics in healthy 
Chinese with ABCG2 34G>A and 421C>A homozygote or compound 
heterozy gote. 
JPharmacol Exp Ther .2015;354(3):310 -315.
Leo Document ID = 12ff9aea-8f09-411a-9bf2-2305c169a69d
Approver: 
Approval Date & Time: 22-Dec-2021 14:39:57 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 22-Dec-2021 15:40:28 GMT
Signature meaning: Approved
PPD
PPD